Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

First International Summit on Interventional Pharmacoeconomics

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Amit Sanyal, MD: A Clinician’s Perspective

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Varsha Gandhi, PhD, on Ibrutinib

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Oct

Today In Oncology

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Related Videos

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Amit Sanyal, MD: A Clinician’s Perspective

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Varsha Gandhi, PhD, on Ibrutinib

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

HER2-Positive Breast Cancer FDA Approves Triplet for Maintenance Therapy

FDA Approves Belzutifan in Combination With Lenvatinib for Advanced ccRCC

FDA Approves Atezolizumab in Combination With Chemotherapy for Stage III dMMR Colon Cancer

Cancer Statistics 2026: Incidence, Mortality, Survival, and Disparities in U.S. Oncology

FDA Approves First-Line Pirtobrutinib for CLL-SLL